Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Will Develop Predix S1P1 Modulators For Autoimmune Diseases

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen will license preclinical S1P1 modulators from Predix for $20 mil. plus additional milestone payments up to $287.5 mil.

You may also be interested in...



Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”

Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”

Roche, Actelion To Develop S1P1 Receptor Agonist For Autoimmune Disease

Roche will pay Actelion $75 mil. up-front for co-development and co-marketing rights to the clinical program, now in Phase I.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel